跳轉至內容
Merck
全部照片(1)

Key Documents

1375502

USP

甲苯咪唑

United States Pharmacopeia (USP) Reference Standard

同義詞:

5-苯甲酰-2-苯并咪唑胺甲酸甲酯, 甲基N-(5-苯甲酰基-1H-苯并咪唑-2-基)氨基甲酸酯, 甲苯咪唑

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C16H13N3O3
CAS號碼:
分子量::
295.29
Beilstein:
759809
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

mebendazole

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccccc3

InChI

1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)

InChI 密鑰

OPXLLQIJSORQAM-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Mebendazole USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Mebendazole Tablets
  • Mebendazole Oral Suspension
  • Fenbendazole
  • Pimozide Tablets
  • Pimozide

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

R W Ammann et al.
Journal of hepatology, 29(6), 994-998 (1999-01-06)
Long-term chemotherapy of human alveolar echinococcosis with benzimidazole compounds (mebendazole, albendazole) has been shown to be primarily parasitostatic, but its curative (parasitocidal) efficacy is debated. This article reports on a 67-year-old male patient with non-resectable alveolar echinococcosis of the liver
[Nonspecific abdominal symptoms. What is going on in the intestine?].
Peter Stiefelhagen
MMW Fortschritte der Medizin, 156(21-22), 44-44 (2015-01-23)
Cong-Shan Liu et al.
Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, 27(6), 513-519 (2010-03-18)
Mebendazole is currently used in the treatment of hydatid disease. Its poor absorption from the gastrointestinal tract and low bioavailability aroused further research on new formulations of mebendazole to increase the bioavailability and improve the therapeutic efficacy. This review summarizes
A Bennett et al.
Parasitology today (Personal ed.), 16(2), 71-74 (2000-02-01)
The widespread use of mebendazole and albendazole for treating intestinal nematode infections in human populations is raising concerns that careful monitoring pro- cedures should be in place to identify any emergence of drug resistance. In this article, Andy Bennett and
T Inaoka et al.
[Hokkaido igaku zasshi] The Hokkaido journal of medical science, 62(1), 54-67 (1987-01-01)
The effects of the mebendazole, albendazole and ivermectin on secondary multilocular echinococcosis in Chinese hamsters infected with intraperitoneal inoculation of protoscolices and in rats infected with transportal inoculation of protoscolices were investigated. A reduction in weight of the hydatids greater

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務